{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T01:05:52Z","timestamp":1785805552493,"version":"3.56.0"},"reference-count":77,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Group B Streptococcus (GBS) remains a major cause of early- and late-onset neonatal sepsis worldwide, despite the widespread use of intrapartum antibiotic prophylaxis (IAP). \u03b2-lactam antibiotics, including penicillin G and ampicillin, remain the cornerstone of both GBS prophylaxis and neonatal treatment, supported by sustained susceptibility, favorable pharmacokinetics, and extensive clinical experience. However, increasing global resistance to macrolides and lincosamides has markedly reduced the reliability of clindamycin and erythromycin, which are commonly used as second-line agents in women with severe penicillin allergy. This narrative review summarizes current evidence on antibiotic strategies for the prevention and treatment of neonatal GBS disease, with a particular focus on antimicrobial resistance patterns and their clinical implications. Available surveillance data demonstrate substantial geographic variability in resistance but consistently low resistance to \u03b2-lactams and vancomycin. These trends have expanded the role of vancomycin in IAP for women with high-risk \u03b2-lactam allergy and in neonatal treatment when first-line agents are contraindicated. Alternative agents such as linezolid and teicoplanin exhibit activity against GBS, but their use remains limited by sparse neonatal data and pharmacokinetic variability. Ongoing antimicrobial surveillance, susceptibility-guided therapy, and stewardship initiatives are essential to preserve effective GBS prevention and treatment strategies.<\/jats:p>","DOI":"10.3390\/antibiotics15030306","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T10:11:12Z","timestamp":1773828672000},"page":"306","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Antibiotic Prophylaxis and Treatment of Neonatal Group B Streptococcus Disease in the Era of Antimicrobial Resistance"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6040-2381","authenticated-orcid":false,"given":"Chryssoula","family":"Tzialla","sequence":"first","affiliation":[{"name":"Neonatal Intensive Care Unit, ASST Papa Giovanni XXIII, 24127 Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6014-9374","authenticated-orcid":false,"given":"Serena","family":"Salom\u00e8","sequence":"additional","affiliation":[{"name":"Division of Neonatology, Department of Translational Medical Sciences, University of Naples Federico II, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8473-6861","authenticated-orcid":false,"given":"Vito","family":"Mond\u00ec","sequence":"additional","affiliation":[{"name":"Neonatology and Neonatal Intensive Care Unit, Azienda Ospedaliera San Giovanni-Addolorata, 00184 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9878-9227","authenticated-orcid":false,"given":"Vincenzo","family":"Salvo","sequence":"additional","affiliation":[{"name":"Neonatal Intensive Care Unit, Ospedale \u201cGiovanni Paolo II\u201d, 97100 Ragusa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3534-7499","authenticated-orcid":false,"given":"Alberto","family":"Berardi","sequence":"additional","affiliation":[{"name":"Neonatal Intensive Care Unit, Women\u2019s and Children\u2019s Health Department, University Hospital of Modena, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e00154-22","DOI":"10.1128\/cmr.00154-22","article-title":"Group B Streptococcal Infections in Pregnancy and Early Life","volume":"38","author":"Manuel","year":"2025","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e00079-21","DOI":"10.1128\/cmr.00079-21","article-title":"Group B Streptococcal Neonatal Meningitis","volume":"35","author":"Tavares","year":"2022","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1542\/pir.2023-006154","article-title":"Neonatal Group B Streptococcus Disease","volume":"45","author":"Coggins","year":"2024","journal-title":"Pediatr. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e20191881","DOI":"10.1542\/peds.2019-1881","article-title":"Management of Infants at Risk for Group B Streptococcal Disease","volume":"144","author":"Puopolo","year":"2019","journal-title":"Pediatrics"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e807","DOI":"10.1016\/S2214-109X(22)00093-6","article-title":"Group B Streptococcus Infection during Pregnancy and Infancy: Estimates of Regional and Global Burden","volume":"10","author":"Procter","year":"2022","journal-title":"Lancet Glob. Health"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S1305","DOI":"10.1016\/j.ajog.2022.07.051","article-title":"Group B Streptococcus and the Risk of Perinatal Morbidity and Mortality Following Term Labor","volume":"228","author":"Stephens","year":"2023","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"ACOG Committee (2020). Prevention of Group B Streptococcal Early-Onset Disease in Newborns: ACOG Committee Opinion, Number 797. Obstet. Gynecol., 135, e51\u2013e72.","DOI":"10.1097\/AOG.0000000000003668"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/MOP.0000000000001223","article-title":"20 Million Pregnant Women with Group B Streptococcus Carriage: Consequences, Challenges, and Opportunities for Prevention","volume":"35","author":"Paul","year":"2023","journal-title":"Curr. Opin. Pediatr."},{"key":"ref_9","first-page":"CD007467","article-title":"Intrapartum Antibiotics for Known Maternal Group B Streptococcal Colonization","volume":"2016","author":"Ohlsson","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"RCOG (2017). Prevention of Early-onset Neonatal Group B Streptococcal Disease: Green-top Guideline No. 36. BJOG Int. J. Obstet. Gynaecol., 124, e280\u2013e305.","DOI":"10.1111\/1471-0528.14821"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"102748","DOI":"10.1016\/j.eclinm.2024.102748","article-title":"Intrapartum Antibiotic Prophylaxis to Prevent Group B Streptococcal Infections in Newborn Infants: A Systematic Review and Meta-Analysis Comparing Various Strategies","volume":"74","author":"Panneflek","year":"2024","journal-title":"eClinicalMedicine"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Furuta, A., Brokaw, A., Manuel, G., Dacanay, M., Marcell, L., Seepersaud, R., Rajagopal, L., and Adams Waldorf, K. (2022). Bacterial and Host Determinants of Group B Streptococcal Infection of the Neonate and Infant. Front. Microbiol., 13.","DOI":"10.3389\/fmicb.2022.820365"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/cid\/cit337","article-title":"Emerging Trends in the Epidemiology of Invasive Group B Streptococcal Disease in England and Wales, 1991\u20132010","volume":"57","author":"Lamagni","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"9539","DOI":"10.1038\/s41598-020-66214-3","article-title":"Increasing Incidence of Group B Streptococcus Neonatal Infections in the Netherlands Is Associated with Clonal Expansion of CC17 and CC23","volume":"10","author":"Jamrozy","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.3201\/eid2611.201669","article-title":"Multidrug-Resistant Hypervirulent Group B Streptococcus in Neonatal Invasive Infections, France, 2007\u20132019","volume":"26","author":"Plainvert","year":"2020","journal-title":"Emerg. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa2116045","article-title":"Potential for Maternally Administered Vaccine for Infant Group B Streptococcus","volume":"389","author":"Madhi","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/INF.0000000000003380","article-title":"Antimicrobial Susceptibility Profiles Among Neonatal Early-Onset Sepsis Pathogens","volume":"41","author":"Flannery","year":"2022","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e02238-17","DOI":"10.1128\/AAC.02238-17","article-title":"Pharmacokinetics of Penicillin G in Preterm and Term Neonates","volume":"62","author":"Padari","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1055\/s-0040-1718880","article-title":"Ampicillin Dose for Early and Late-Onset Group B Streptococcal Disease in Neonates","volume":"39","author":"Lim","year":"2022","journal-title":"Am. J. Perinatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/S0140-6736(17)31002-4","article-title":"Neonatal Sepsis","volume":"390","author":"Shane","year":"2017","journal-title":"Lancet"},{"key":"ref_21","unstructured":"National Institute for Health and Care Excellence Guideline (2026, February 15). Neonatal Infection: Antibiotics for Prevention and Treatment (NG195). Available online: https:\/\/www.Nice.Org.Uk\/Guidance\/Ng195\/Resources\/Neonatal-Infection-Antibiotics-for-Prevention-and-Treatment-Pdf-66142083827653."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/tropej\/fmq012","article-title":"Ten Days vs. 14 Days Antibiotic Therapy in Culture-Proven Neonatal Sepsis","volume":"56","author":"Gathwala","year":"2010","journal-title":"J. Trop. Pediatr."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"8","DOI":"10.7199\/ped.oncall.2020.18","article-title":"Ten Days Versus Fourteen Days Antibiotic Therapy in Culture Proven Neonatal Sepsis: Single Center Egyptian Experience","volume":"17","author":"Salama","year":"2020","journal-title":"Pediatr. Oncall"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s12098-021-03794-6","article-title":"Ten Versus 14 Days of Antibiotic Therapy in Culture-Proven Neonatal Sepsis: A Randomized, Controlled Trial","volume":"89","author":"Reddy","year":"2022","journal-title":"Indian J. Pediatr."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/INF.0000000000003314","article-title":"Duration of Antibiotic Therapy in Neonatal Gram-Negative Bacterial Sepsis\u201410 Days Versus 14 Days: A Randomized Controlled Trial","volume":"41","author":"Fursule","year":"2022","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"fmad036","DOI":"10.1093\/tropej\/fmad036","article-title":"Ten- vs. 14-Day Antibiotic Therapy for Culture-Positive Neonatal Sepsis","volume":"69","author":"Islam","year":"2023","journal-title":"J. Trop. Pediatr."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/tropej\/fml054","article-title":"Randomized Controlled Trial of 7-Day vs. 14-Day Antibiotics for Neonatal Sepsis","volume":"52","author":"Chowdhary","year":"2006","journal-title":"J. Trop. Pediatr."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1136\/archdischild-2024-328232","article-title":"Seven-Day versus 14-Day Antibiotic Course for Culture-Proven Neonatal Sepsis: A Multicentre Randomised Non-Inferiority Trial in a Low and Middle-Income Country","volume":"110","author":"Dutta","year":"2025","journal-title":"Arch. Dis. Child.-Fetal Neonatal Ed."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/jpc.13518","article-title":"Seven versus 10 Days Antibiotic Therapy for Culture-proven Neonatal Sepsis: A Randomised Controlled Trial","volume":"53","author":"Rohatgi","year":"2017","journal-title":"J. Paediatr. Child Health"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e200593","DOI":"10.1001\/jamapediatrics.2020.0593","article-title":"Early-Onset Neonatal Sepsis 2015 to 2017, the Rise of Escherichia coli, and the Need for Novel Prevention Strategies","volume":"174","author":"Stoll","year":"2020","journal-title":"JAMA Pediatr."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e2022058813","DOI":"10.1542\/peds.2022-058813","article-title":"Late-Onset Sepsis Among Very Preterm Infants","volume":"150","author":"Flannery","year":"2022","journal-title":"Pediatrics"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"6626983","DOI":"10.1155\/2021\/6626983","article-title":"A Systemic Review and Meta-analysis of the Leading Pathogens Causing Neonatal Sepsis in Developing Countries","volume":"2021","author":"Zelellw","year":"2021","journal-title":"BioMed Res. Int."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e2022057510","DOI":"10.1542\/peds.2022-057510","article-title":"Duration of Antibiotic Therapy for Bacterial Meningitis in Young Infants: A Systematic Review","volume":"150","author":"Schroeder","year":"2022","journal-title":"Pediatrics"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0140-6736(24)00495-1","article-title":"Neonatal Bacterial Sepsis","volume":"404","author":"Strunk","year":"2024","journal-title":"Lancet"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ogc.2023.02.009","article-title":"Group B Streptococcus in Pregnancy","volume":"50","author":"Mei","year":"2023","journal-title":"Obstet. Gynecol. Clin. N. Am."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/GRF.0000000000000884","article-title":"Group B Streptococcus and Intraamniotic Inflammation and Infection","volume":"67","author":"Afsari","year":"2024","journal-title":"Clin. Obstet. Gynecol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Snider, J.B., Mithal, L.B., Kwah, J.H., Rhodes, N.J., and Son, M. (2023). Antibiotic Choice for Group B Streptococcus Prophylaxis in Mothers with Reported Penicillin Allergy and Associated Newborn Outcomes. BMC Pregnancy Childbirth, 23.","DOI":"10.1186\/s12884-023-05697-0"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Hsu, C.-Y., Moradkasani, S., Suliman, M., Uthirapathy, S., Zwamel, A.H., Hjazi, A., Vashishth, R., and Beig, M. (2025). Global Patterns of Antibiotic Resistance in Group B Streptococcus: A Systematic Review and Meta-Analysis. Front. Microbiol., 16.","DOI":"10.3389\/fmicb.2025.1541524"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1038\/s41390-022-02375-3","article-title":"Evolving Antibiotic Resistance in Group B Streptococci Causing Invasive Infant Disease: 1970\u20132021","volume":"93","author":"Sabroske","year":"2023","journal-title":"Pediatr. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e70087","DOI":"10.1002\/mbo3.70087","article-title":"Global Antimicrobial Resistance Trends in Group B Streptococcus Isolates From Pregnant Women: Systematic Review and Meta-Analysis","volume":"14","author":"Bostanghadiri","year":"2025","journal-title":"MicrobiologyOpen"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Abu Shqara, R., Or, S., Goldinfeld, G., Ganem, N., Lowenstein, L., and Frank Wolf, M. (2025). Maternal and Microbiological Outcomes in GBS-Positive Patients Receiving Intrapartum Ampicillin versus Clindamycin: A Retrospective Cohort Study. Gynecol. Obstet. Investig., Epub ahead print.","DOI":"10.1159\/000549302"},{"key":"ref_42","unstructured":"Centers for Disease Control and Prevention (2026, February 15). ABCs Bact Facts Interactive Data Dashboard, Available online: https:\/\/www.Cdc.Gov\/Abcs\/Bact-Facts\/Data-Dashboard.Html."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1001\/jamapediatrics.2018.4826","article-title":"Epidemiology of Invasive Early-Onset and Late-Onset Group B Streptococcal Disease in the United States, 2006 to 2015: Multistate Laboratory and Population-Based Surveillance","volume":"173","author":"Nanduri","year":"2019","journal-title":"JAMA Pediatr."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1001\/jamainternmed.2018.7269","article-title":"Epidemiology of Invasive Group B Streptococcal Infections Among Nonpregnant Adults in the United States, 2008-2016","volume":"179","author":"McGee","year":"2019","journal-title":"JAMA Intern. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1097\/INF.0000000000004908","article-title":"Epidemiology of Infant Group B Streptococcus Infection in New Zealand: A 10-Year Retrospective Study","volume":"44","author":"Millar","year":"2025","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Creti, R., Imperi, M., Gherardi, G., Alfarone, G., Marani, I., Vocale, C., Berardi, A., Truocchio, S., and Miselli, F. (2025). Group B Streptococcus (GBS) Carriage in Pregnant Women: Possible Emergence of Rare Serotypes and Antibiotic Resistance in Neonatal Disease. Microorganisms, 13.","DOI":"10.3390\/microorganisms13071496"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Creti, R., Imperi, M., Berardi, A., Lindh, E., Alfarone, G., Pataracchia, M., Recchia, S., and The Italian Network on Neonatal and Infant GBS Infections (2021). Invasive Group B Streptococcal Disease in Neonates and Infants, Italy, Years 2015\u20132019. Microorganisms, 9.","DOI":"10.3390\/microorganisms9122579"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Imperi, M., Gherardi, G., Alfarone, G., and Creti, R. (2024). Group B Streptococcus Infections in Non-Pregnant Adults, Italy, 2015\u20132019. Pathogens, 13.","DOI":"10.3390\/pathogens13090807"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1038\/s41598-024-54521-y","article-title":"Macrolide and Lincosamide Resistance of Streptococcus Agalactiae in Pregnant Women in Poland","volume":"14","author":"Ratajczak","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Oppegaard, O., Skrede, S., Mylvaganam, H., and Kittang, B.R. (2020). Emerging Threat of Antimicrobial Resistance in \u03b2-Hemolytic Streptococci. Front. Microbiol., 11.","DOI":"10.3389\/fmicb.2020.00797"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12941-023-00563-5","article-title":"Correction: Maternal Colonization with Group B Streptococcus and Antibiotic Resistance in China: Systematic Review and Meta-Analyses","volume":"22","author":"Wang","year":"2023","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/1040841X.2020.1758626","article-title":"A Review of Antibiotic Resistance in Group B Streptococcus: The Story so Far","volume":"46","author":"Hayes","year":"2020","journal-title":"Crit. Rev. Microbiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1055\/s-0038-1675622","article-title":"The Effect of Intrapartum Vancomycin on Vaginal Group B Streptococcus Colony Counts","volume":"36","author":"Hamel","year":"2019","journal-title":"Am. J. Perinatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1080\/14767058.2017.1306049","article-title":"Transplacental Passage of Vancomycin","volume":"31","author":"Towers","year":"2018","journal-title":"J. Matern. Fetal Neonatal Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/AOG.0000000000005843","article-title":"Vancomycin Concentrations in Umbilical Cord Blood After Intrapartum Exposure","volume":"145","author":"Coggins","year":"2025","journal-title":"Obstet. Gynecol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1080\/14767058.2020.1733520","article-title":"Vancomycin during Delivery Hospitalizations for Women with Group B Streptococcus","volume":"35","author":"Duffy","year":"2022","journal-title":"J. Matern. Fetal Neonatal Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1515\/jpm-2021-0558","article-title":"Evaluation of Appropriate Vancomycin Prescribing for the Prevention of Newborn Group B Streptococcal Infections in a Community Hospital Obstetrics Service","volume":"50","author":"Assabahi","year":"2022","journal-title":"J. Perinat. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1093\/cid\/ciaa151","article-title":"Multistate, Population-Based Distributions of Candidate Vaccine Targets, Clonal Complexes, and Resistance Features of Invasive Group B Streptococci Within the United States, 2015\u20132017","volume":"72","author":"McGee","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1001\/jama.299.17.2056","article-title":"Epidemiology of Invasive Group B Streptococcal Disease in the United States, 1999\u20132005","volume":"299","author":"Phares","year":"2008","journal-title":"JAMA"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7754\/Clin.Lab.2024.240742","article-title":"Epidemiology and Antibiotic Resistance of Neonatal Invasive Group B Streptococcus Disease: A Retrospective Study in Fuzhou, China, 2012\u20132021","volume":"71","author":"Zhong","year":"2025","journal-title":"Clin. Lab."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e01109-22","DOI":"10.1128\/aac.01109-22","article-title":"Association between Vancomycin Pharmacokinetic Parameters and Clinical and Microbiological Efficacy in a Cohort of Neonatal Patients","volume":"66","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"54","DOI":"10.18773\/austprescr.2025.013","article-title":"Safe and Effective Use of Vancomycin","volume":"48","author":"Legg","year":"2025","journal-title":"Aust. Prescr."},{"key":"ref_63","unstructured":"(2026, February 15). Tedizolid FDA, Available online: https:\/\/www.Accessdata.Fda.Gov\/Drugsatfda_docs\/Label\/2019\/205436s005lbl.Pdf."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.jiac.2018.04.006","article-title":"Comparative Study on Safety of Linezolid and Vancomycin in the Treatment of Infants and Neonates for Gram-Positive Bacterial Infections","volume":"24","author":"Shibata","year":"2018","journal-title":"J. Infect. Chemother."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1111\/jcpt.13652","article-title":"Effects of Linezolid on the Haematological System in Very Low Birth Weight Infants: A Single-centre Retrospective Study","volume":"47","author":"Bu","year":"2022","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1007\/s00228-024-03740-3","article-title":"Evaluation of Pharmacokinetic Target Attainment and Hematological Toxicity of Linezolid in Pediatric Patients","volume":"80","author":"Abouelkheir","year":"2024","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s00431-025-06548-0","article-title":"Clinical Use and Safety Profile of Intravenous Linezolid in Hospitalised Children: A Retrospective Cohort Experience","volume":"184","author":"Erat","year":"2025","journal-title":"Eur. J. Pediatr."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e00294-25","DOI":"10.1128\/aac.00294-25","article-title":"Pharmacokinetics and Hematologic Toxicity of Linezolid in Children: A Prospective, Two-Center Cohort Study","volume":"69","author":"Zhu","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e01299-24","DOI":"10.1128\/aac.01299-24","article-title":"Population Pharmacokinetics and Clinical Assessment of Linezolid in Pediatric Bacterial Infections","volume":"69","author":"Tian","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"dlac088","DOI":"10.1093\/jacamr\/dlac088","article-title":"Five-Year Analysis of the in Vitro Activity of Tedizolid against a Worldwide Collection of Indicated Species Causing Clinical Infections: Results from the Surveillance of Tedizolid Activity and Resistance (STAR) Programme","volume":"4","author":"Carvalhaes","year":"2022","journal-title":"JAC-Antimicrob. Resist."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/INF.0000000000004807","article-title":"A Phase 3 Study of the Safety and Efficacy of Tedizolid Phosphate in Patients <12 Years of Age with Acute Bacterial Skin and Skin Structure Infections","volume":"44","author":"Mngqibisa","year":"2025","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"5529","DOI":"10.2147\/IDR.S549854","article-title":"A Comprehensive Analysis of Teicoplanin Population Pharmacokinetic Models in Pediatric Populations: Age-Dependent Variability and Implications for Dose Optimization","volume":"18","author":"Yu","year":"2025","journal-title":"Infect. Drug Resist."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/bcp.70309","article-title":"Pharmacokinetics of Teicoplanin in Paediatric Patients\u2014A Systematic Review of Current Literature","volume":"92","author":"Wijnen","year":"2025","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s40262-025-01483-7","article-title":"Pharmacokinetics and Target Attainment of Teicoplanin: A Systematic Review","volume":"64","author":"Mouton","year":"2025","journal-title":"Clin. Pharmacokinet."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.amjms.2025.10.023","article-title":"Streptococcal Infections: Emerging Trends, Clinical Spectrum and Global Prevention Effort","volume":"371","author":"Bennett","year":"2025","journal-title":"Am. J. Med. Sci."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1016\/S0140-6736(24)00878-X","article-title":"Expanding Antibiotic, Vaccine, and Diagnostics Development and Access to Tackle Antimicrobial Resistance","volume":"403","author":"Laxminarayan","year":"2024","journal-title":"Lancet"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e01991-21","DOI":"10.1128\/aac.01991-21","article-title":"Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed","volume":"66","author":"Butler","year":"2022","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/15\/3\/306\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T10:26:37Z","timestamp":1773829597000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/15\/3\/306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":77,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["antibiotics15030306"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics15030306","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]}}}